Arecor Therapeutics plc

DB:6UI Stock Report

Market Cap: €34.6m

Arecor Therapeutics Future Growth

Future criteria checks 2/6

Arecor Therapeutics's earnings are forecast to decline at 1.8% per annum while its annual revenue is expected to grow at 35.2% per year. EPS is expected to decline by 1.8% per annum.

Key information

-1.8%

Earnings growth rate

-1.8%

EPS growth rate

Biotechs earnings growth43.1%
Revenue growth rate35.2%
Future return on equityn/a
Analyst coverage

Low

Last updated12 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:6UI - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202612N/A-2N/A2
12/31/20259-6-3-33
12/31/20246-8-8-93
6/30/20245-9-6-6N/A
3/31/20245-9-6-6N/A
12/31/20235-9-6-6N/A
9/30/20234-9-9-8N/A
6/30/20233-9-11-11N/A
3/31/20233-9-11-11N/A
12/31/20222-9-11-11N/A
9/30/20222-8-10-9N/A
6/30/20221-7-8-8N/A
3/31/20221-7-7-7N/A
12/31/20211-6-6-5N/A
9/30/20211-5-4-4N/A
6/30/20211-5-3-3N/A
3/31/20212-4-3-2N/A
12/31/20202-3-2-2N/A
12/31/20192-200N/A
5/31/20191-2-3-3N/A
5/31/20181-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6UI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6UI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6UI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6UI's revenue (35.2% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 6UI's revenue (35.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 6UI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y